Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 341

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 341
---
.01 per share to $0.01 per share and the addition of performance and vesting conditions, not currently considered probable of achievement, related to corporate transactions. In the year ended May 31, 2025, stock -basedcompensation expense amounted to $24,312, which is included in research and development expenses. In the year ended May 31, 2024, stock -basedcompensation expense amounted to $194,846, of which $182,912 is included in research and development expenses and $11,934 is included in general and administrative expenses.. As of May 31, 2025, there is no unrecognized stock -basedcompensation expense related to options for which vesting is considered probable. As of May 31, 2025, unrecognized stock -basedcompensation expense related to options for which vesting is not considered probable was $1,093,712. In the year ended May 31, 2023, DiamiR issued 132,000 restricted stock units, vesting upon a change in control or public listing of DiamiR’s common stock. In the year ended May 31, 2024, concurrent with the modification of stock options described above, DiamiR terminated outstanding restricted stock units representing 44,000shares. Vesting of the units is not considered probable and no compensation expense has been recognized through the year ended May 31, 2025. The grant -datefair value and unrecognized compensation expense as of May 31, 2023 related to the restricted stock units amounts to $652,080. There was no additional stock option activity in the year ended May 31, 2025.

190

Laboratory Acquisition and Intangible Assets On April 15, 2021, pursuant to an Asset Purchase Agreement, DiamiR acquired certain laboratory assets, facilities and operations from Interpace, a provider of molecular diagnostic tests. The total purchase consideration consisted of 42,820shares DiamiR common stock with an estimated fair value of $300,000. At acquisition, the laboratory was in active operation, providing services to third -parties, and DiamiR accounted for the acquisition as the purchase of a business in accordance with FASB ASC Topic 805 Business Combinations. Accordingly, DiamiR recorded the assets acquired at their estimated fair values. The following table summarizes the purchase price allocation:

| Assets acquired:            |     | Estimated  
 fair value |         |
|:----------------------------|:----|:-----------|